ESMO 2018 | Clinical trial updates on patient responses with triplet therapy

Jeffrey Weber, MD, PhD, of the Perlmutter Cancer Center, New York, NY, explores overall survival and drug toxicity in the latest clinical trials testing pembrolizumab, dabrafenib, and trametinib, in patients with melanoma. Ongoing trials investigating this triplet treatment are awaiting data on the progression-free survival of patients, which could determine if the KEYNOTE-001 study is worth continuing into a phase III trial. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.